Alnylam Pharmaceuticals
ALNY
#689
Rank
โ‚น3.503 T
Marketcap
โ‚น26,240
Share price
1.13%
Change (1 day)
-7.44%
Change (1 year)
Alnylam Pharmaceuticals Inc. is a biopharmaceutical company focused on the R&D and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases.

EPS for Alnylam Pharmaceuticals (ALNY)

EPS in 2026 (TTM): โ‚น346.28

According to Alnylam Pharmaceuticals 's latest financial reports the company's current EPS (TTM) is โ‚น365.93. In 2025 the company made an earnings per share (EPS) of โ‚น173.79.

EPS history for Alnylam Pharmaceuticals from 2012 to 2026

Annual EPS

Year EPS Change
2026 (TTM)โ‚น346.2899.25%
2025โ‚น173.79
2023-โ‚น340.83-62%
2022-โ‚น896.9729.03%
2021-โ‚น695.17-3.36%
2020-โ‚น719.31-8.48%
2019-โ‚น785.937.67%
2018-โ‚น729.9339.74%
2017-โ‚น522.3512.94%
2016-โ‚น462.4838.84%
2015-โ‚น333.10-32.88%
2014-โ‚น496.28259.44%
2013-โ‚น138.07-31.25%
2012-โ‚น200.83

EPS for similar companies or competitors

Company EPS EPS differencediff. Country
Novartis
NVS
โ‚น677.80 85.22%๐Ÿ‡จ๐Ÿ‡ญ Switzerland
Sanofi
SNY
โ‚น247.14-32.46%๐Ÿ‡ซ๐Ÿ‡ท France
Regeneron Pharmaceuticals
REGN
โ‚น4,106 1,022.16%๐Ÿ‡บ๐Ÿ‡ธ USA
Sarepta Therapeutics
SRPT
-โ‚น55.03-115.04%๐Ÿ‡บ๐Ÿ‡ธ USA
Regulus Therapeutics
RGLS
-โ‚น70.48-119.26%๐Ÿ‡บ๐Ÿ‡ธ USA
OPKO Health
OPK
-โ‚น26.07-107.12%๐Ÿ‡บ๐Ÿ‡ธ USA
Teva Pharmaceutical Industries
TEVA
โ‚น132.28-63.85%๐Ÿ‡ฎ๐Ÿ‡ฑ Israel
Arrowhead Pharmaceuticals
ARWR
โ‚น78.21-78.63%๐Ÿ‡บ๐Ÿ‡ธ USA